Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience develops clinical-stage precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform™ to analyze EEG activity, neurocognitive assessments, wearable data and other biomarkers that may identify patient populations for its product candidates.
Company news centers on clinical data, trial initiations and pipeline decisions for programs including ALTO-207 in treatment-resistant depression and major depressive disorder, ALTO-101 in cognitive impairment associated with schizophrenia, and other candidates for bipolar depression, schizophrenia and mental health conditions. Updates also cover financial results, capital activity, regulatory designations, medical-meeting presentations and investor-conference participation.
Alto Neuroscience (NYSE: ANRO) announced that founder and CEO Amit Etkin, M.D., Ph.D. received the Transformational Research Award from the Columbia University VP&S Alumni Association. The honor recognizes alumni making major biomedical research contributions within 25 years of graduation.
Etkin leads Alto’s Precision Psychiatry Platform and a clinical-stage pipeline in multiple mood and psychiatric disorders, with several mid- to late-stage data readouts anticipated over the next two years.
Alto Neuroscience (NYSE: ANRO) reported first quarter 2026 results and pipeline updates. Cash, cash equivalents and restricted cash were $264.2 million as of March 31, 2026, boosted by a $120 million PIPE, and are expected to fund planned operations through 2029.
Alto initiated a Phase 2b TRD trial for ALTO-207, with Phase 3 and potential NDA supported by current cash. The ALTO-101 Phase 2 POC trial missed its primary CIAS EEG endpoint but showed significant effects on several EEG markers of general cognition and sustained attention.
Enhanced eligibility and quality measures in the ALTO-300 and ALTO-100 Phase 2b trials are expected to improve data quality but shift topline readouts to 2027. Q1 2026 R&D expenses were $20.3 million, G&A $6.8 million, and net loss $26.2 million.
Alto Neuroscience (NYSE: ANRO) will participate in two upcoming investor conferences. Management will present at the Bank of America Securities Healthcare Conference on May 13, 2026, in Las Vegas and at the Jefferies Global Healthcare Conference on June 3, 2026, in New York.
Presentations will be available via live webcast and replay on Alto’s investor relations website.
Alto Neuroscience (NYSE: ANRO) presented Phase 2a data for ALTO-207 at the 2026 SOBP Annual Meeting on May 4, 2026. A randomized, single-blind, placebo-controlled trial (n=32) showed statistically significant antidepressant effects on MADRS and CGI-S through Week 8 and favorable tolerability.
Key metrics: mean pramipexole dose 4.1 mg by Day 8; 60% reached 5 mg by Day 12; MADRS effect sizes Week 6 d=1.67 (p=0.0004) and Week 8 d=1.1 (p=0.025); no ALTO-207 arm discontinuations during maintenance. Phase 2b is ongoing with topline expected in 2H 2027.
Alto Neuroscience (NYSE: ANRO) initiated a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression. The trial will enroll ~178 adults, randomize 1:1 to ALTO-207 or placebo for eight weeks, titrating to 3.2 mg pramipexole/15 mg ondansetron daily.
The design mirrors the PAX-D study and uses MADRS as the primary endpoint aligned with FDA guidance. A prior Phase 2a showed Cohen’s d = 1.1. Topline data are expected in 2H 2027; sites include the US and UK, including NHS centers from PAX-D.
Alto Neuroscience (NYSE: ANRO) reported Phase 2 POC topline results for ALTO-101 in CIAS: the study did not meet primary EEG or cognitive endpoints, though directional EEG signals and a nominally significant theta-ITC result in a more impaired subgroup (n=59, d=0.44, p=0.03) were observed. Alto will not independently advance ALTO-101 and will prioritize ALTO-207, which remains on track to start a Phase 2b in 1H 2026. The company holds $275 million in cash and has a modified-release ALTO-101 formulation being explored for partnering.
Alto Neuroscience (NYSE: ANRO) entered a private placement (PIPE) to raise approximately $120 million in gross proceeds to fund development of ALTO-207 for treatment resistant depression.
Alto sold 2,900,000 common shares at $20.00 and pre-funded warrants for 3,100,000 shares at $19.9999 each. The company expects to start a Phase 2b in H1 2026 and a Phase 3 in early 2027, and estimates pro forma cash of approximately $275 million as of February 28, 2026.
Alto Neuroscience (NYSE:ANRO)/b) reported full year 2025 results and pipeline progress, highlighting the , a $50 million PIPE financing, and a year-end cash balance of $177 million expected to fund operations into 2028. Key clinical milestones include FDA Fast Track for ALTO-101, planned ALTO-207 Phase 2b initiation in 1H 2026, and four near-term data readouts through 2027.
Clinical signals include a PAX-D Cohen's d=0.87 for pramipexole and a meta-analytic Hedges' g=0.64 (p<0.001). Full-year R&D was $45.6M, G&A $20.7M, and net loss $63.2M.
Alto Neuroscience (NYSE: ANRO) said members of management will present in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.
The presentation will stream live via a webcast on Alto's Investors Events and Presentations page, and a replay will be available after the event.
Alto Neuroscience (NYSE: ANRO) said management will attend two investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference (March 2-5) with a fireside chat on March 3, 2026 at 1:50 pm EST, and Jefferies Biotech on the Beach Summit (March 10-11) for one-on-one meetings.
Presentations will be available via live webcast on Alto's Investors Events and Presentations page, with replays posted after the sessions.